GlaxoSmithKline (GSK) Shares Up 0% Following Analyst Upgrade

GlaxoSmithKline plc (LON:GSK) shares shot up 0% during trading on Friday after Deutsche Bank raised their price target on the stock from GBX 1,380 to GBX 1,440. Deutsche Bank currently has a hold rating on the stock. GlaxoSmithKline traded as high as GBX 1,358.40 ($18.42) and last traded at GBX 1,353 ($18.35). 12,663,661 shares traded hands during trading, an increase of 51% from the average session volume of 8,400,000 shares. The stock had previously closed at GBX 1,353 ($18.35).

GSK has been the topic of a number of other reports. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a GBX 1,570 ($21.29) target price on shares of GlaxoSmithKline in a research note on Monday, October 2nd. Liberum Capital reiterated a “buy” rating and issued a GBX 1,760 ($23.87) target price on shares of GlaxoSmithKline in a research note on Wednesday, October 25th. Beaufort Securities reiterated a “buy” rating and issued a GBX 1,800 ($24.41) target price on shares of GlaxoSmithKline in a research note on Monday, October 23rd. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline in a research note on Wednesday, September 20th. Finally, UBS Group upgraded shares of GlaxoSmithKline to a “buy” rating and set a GBX 1,550 ($21.02) target price on the stock in a research note on Monday, November 27th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of GBX 1,555.24 ($21.09).

In other news, insider Patrick Vallance sold 20,000 shares of the firm’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of GBX 1,310 ($17.77), for a total transaction of £262,000 ($355,302.41). Also, insider Urs Rohner acquired 473 shares of GlaxoSmithKline stock in a transaction dated Wednesday, October 25th. The shares were acquired at an average cost of GBX 1,518 ($20.59) per share, with a total value of £7,180.14 ($9,737.10). Insiders have bought a total of 502 shares of company stock valued at $756,702 over the last ninety days.

The stock has a market cap of $67,080.00 and a price-to-earnings ratio of 2,818.75.

GlaxoSmithKline (LON:GSK) last announced its quarterly earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). GlaxoSmithKline had a net margin of 17.79% and a return on equity of 461.88%. The firm had revenue of GBX 784.30 billion during the quarter.

The company also recently declared a dividend, which was paid on Thursday, January 11th. Investors of record on Thursday, November 9th were issued a dividend of GBX 19 ($0.26) per share. This represents a yield of 1.41%. The ex-dividend date was Thursday, November 9th.

TRADEMARK VIOLATION WARNING: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/14/glaxosmithkline-gsk-shares-up-0-following-analyst-upgrade.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply